search button
Open Access

T1‑2N1M0 triple‑negative breast cancer patients from the SEER database showed potential benefit from post‑mastectomy radiotherapy

  • Authors:
    • Xueying Wang
    • Yingying Xu
    • Shanshan Guo
    • Jiaxin Zhang
    • Masanobu Abe
    • Haosheng Tan
    • Shaojun Wang
    • Ping Chen
    • Liang Zong

  • View Affiliations

  • Published online on: November 21, 2019     https://doi.org/10.3892/ol.2019.11139
  • Pages: 735-744

  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The effects of post‑mastectomy radiotherapy (PMRT) on different subtypes of T1‑2N1M0 breast cancer remain controversial. Patients with T1‑2N1M0 breast cancer treated by mastectomy or mastectomy and PMRT were identified from the 2010‑2013 dataset from the Surveillance, Epidemiology and End Results (SEER) registry. A total of 7,466 patients with the 7th American Joint Committee on Cancer stage (Tumor‑Node‑Metastasis stages 1‑2, 1 and 0, respectively) including 2,760 cases (36.97%) treated by mastectomy and PMRT and 4,706 cases (63.03%) treated by mastectomy alone were analyzed in this study. The follow‑up time for patients in the dataset used from the SEER registry was 0‑59 months. The breast cancer‑specific survival (BCSS) of the patients was derived from the SEER dataset and stratified by treatment approach. A propensity score matching (PSM) analysis (experimental group: Control group ratio, 1:1) was conducted. Using univariate and multivariate analyses Cox proportional hazards analyses, PMRT was identified as an independent prognostic factor for triple‑negative breast cancer (TNBC). Before PSM analysis, the BCSS favored PMRT in the hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)+ (P=0.025) and HR‑/HER2‑ groups (P=0.010) but not in the HR+/HER2‑ (P=0.346) and HR‑/HER2+ (P=0.288) groups. Following PSM analysis, BCSS favored PMRT alone in the TNBC (HR‑/HER2‑) group (P=0.025). Patients with T1‑2N1M0 TNBC may benefit from radiotherapy post‑mastectomy.
View Figures
View References

Related Articles

Journal Cover

January-2020
Volume 19 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Wang X, Xu Y, Guo S, Zhang J, Abe M, Tan H, Wang S, Chen P and Zong L: T1‑2N1M0 triple‑negative breast cancer patients from the SEER database showed potential benefit from post‑mastectomy radiotherapy . Oncol Lett 19: 735-744, 2020
APA
Wang, X., Xu, Y., Guo, S., Zhang, J., Abe, M., Tan, H. ... Zong, L. (2020). T1‑2N1M0 triple‑negative breast cancer patients from the SEER database showed potential benefit from post‑mastectomy radiotherapy . Oncology Letters, 19, 735-744. https://doi.org/10.3892/ol.2019.11139
MLA
Wang, X., Xu, Y., Guo, S., Zhang, J., Abe, M., Tan, H., Wang, S., Chen, P., Zong, L."T1‑2N1M0 triple‑negative breast cancer patients from the SEER database showed potential benefit from post‑mastectomy radiotherapy ". Oncology Letters 19.1 (2020): 735-744.
Chicago
Wang, X., Xu, Y., Guo, S., Zhang, J., Abe, M., Tan, H., Wang, S., Chen, P., Zong, L."T1‑2N1M0 triple‑negative breast cancer patients from the SEER database showed potential benefit from post‑mastectomy radiotherapy ". Oncology Letters 19, no. 1 (2020): 735-744. https://doi.org/10.3892/ol.2019.11139